Please assess the completion status of the following clinical trial:

Trial Title: First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histological or cytological proof of transitional cell carcinoma (TCC) of the bladder, urethra, ureter, or renal pelvis (urothelial carcinoma). Histology may be mixed, but still requires a component of TCC.~* Measurable disease according to RECIST and obtained by imaging within 30 days prior to registration for protocol therapy.~* Must be ineligible for cisplatin, based on the following, within 30 days prior to registration for protocol therapy.~* Prior radiation therapy is allowed to \< 25% of the bone marrow.~* Written informed consent and HIPAA authorization for release of personal health information.~* Age \> 18 years at the time of consent.~* Females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time consent is signed until 8 weeks after treatment discontinuation.~* Females of childbearing potential must have a negative pregnancy test within 7 days prior to prior to registration for protocol therapy.~* Females must not be breastfeeding.~Exclusion Criteria:~* No prior chemotherapy for metastatic disease. Prior chemotherapy in the neoadjuvant/adjuvant setting is allowed if completed at least 12 months prior to registration for protocol therapy.~* No active CNS metastases or leptomeningeal metastases. Patients with neurological symptoms must undergo a head CT scan or brain MRI to exclude brain metastasis.~* No prior malignancy is allowed except for adequately treated basal cell or adequately treated squamous cell skin cancer, in situ cervical cancer, Gleason ≤ grade 7 prostate cancers (treated definitively with no evidence of PSA progression), or other cancer for which the patient has been disease-free for at least 5 years.~* No treatment with any anticancer therapy or investigational agent within 30 days prior to registration for protocol therapy.~* No known hypersensitivity to any protocol treatment.~* No prior treatment with mTOR inhibitor (sirolimus, temsirolimus, everolimus).~* No history of immunization with attenuated live vaccines within one week prior to registration for protocol therapy or during study period.~* No severely impaired lung function as defined as spirometry and DLCO that is 50% of the normal predicted value and/or 02 saturation that is 88% or less at rest on room air.~* No uncontrolled diabetes as defined by fasting serum glucose \>1.5 x ULN.~* No active (acute or chronic) or uncontrolled severe infections.~* No liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis.~* No known history of HIV seropositivity.~* No impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of everolimus (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection).~* No active, bleeding diathesis.~* No history of major surgery (defined as requiring general anesthesia) or significant traumatic injury within 30 days prior to registration for protocol therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: ACTIVE_COMPARATOR): Single-agent everolimus (enrollment limited to patients with patients with creatinine clearance \< 60 ml/min AND Karnofsky performance status of 60-70%)
- Cohort 2 (Type: ACTIVE_COMPARATOR): Everolimus plus paclitaxel (enrollment limited to patients with creatinine clearance \< 60 ml/min OR Karnofsky performance status of 60-70%)

Based on this trial design, predict the completion outcome and termination type (if applicable).